These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28180075)

  • 1. Independent value added by diffusion MRI for prediction of cognitive function in older adults.
    Scott JA; Tosun D; Braskie MN; Maillard P; Thompson PM; Weiner M; DeCarli C; Carmichael OT;
    Neuroimage Clin; 2017; 14():166-173. PubMed ID: 28180075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
    van Loenhoud AC; van der Flier WM; Wink AM; Dicks E; Groot C; Twisk J; Barkhof F; Scheltens P; Ossenkoppele R;
    Neurology; 2019 Jul; 93(4):e334-e346. PubMed ID: 31266904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
    Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
    Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
    Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
    J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
    Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
    J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study.
    Wang YL; Chen W; Cai WJ; Hu H; Xu W; Wang ZT; Cao XP; Tan L; Yu JT;
    J Alzheimers Dis; 2020; 73(2):759-768. PubMed ID: 31839612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
    Schmand B; Eikelenboom P; van Gool WA;
    J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.
    Risacher SL; McDonald BC; Tallman EF; West JD; Farlow MR; Unverzagt FW; Gao S; Boustani M; Crane PK; Petersen RC; Jack CR; Jagust WJ; Aisen PS; Weiner MW; Saykin AJ;
    JAMA Neurol; 2016 Jun; 73(6):721-32. PubMed ID: 27088965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of Vascular Risk with Cognition, Brain Glucose Metabolism, and Clinical Progression in Cognitively Intact Elders.
    Yu GX; Zhang T; Hou XH; Ou YN; Hu H; Wang ZT; Guo Y; Xu W; Tan L; Yu JT; Tan L;
    J Alzheimers Dis; 2021; 80(1):321-330. PubMed ID: 33523005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort.
    Dufouil C; Dubois B; Vellas B; Pasquier F; Blanc F; Hugon J; Hanon O; Dartigues JF; Harston S; Gabelle A; Ceccaldi M; Beauchet O; Krolak-Salmon P; David R; Rouaud O; Godefroy O; Belin C; Rouch I; Auguste N; Wallon D; Benetos A; Pariente J; Paccalin M; Moreaud O; Hommet C; Sellal F; Boutoleau-Bretonniére C; Jalenques I; Gentric A; Vandel P; Azouani C; Fillon L; Fischer C; Savarieau H; Operto G; Bertin H; Chupin M; Bouteloup V; Habert MO; Mangin JF; Chêne G;
    Alzheimers Res Ther; 2017 Aug; 9(1):67. PubMed ID: 28851447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
    Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
    J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
    Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
    JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.
    Insel PS; Mattsson N; Mackin RS; Schöll M; Nosheny RL; Tosun D; Donohue MC; Aisen PS; Jagust WJ; Weiner MW;
    Neurology; 2016 May; 86(20):1887-96. PubMed ID: 27164667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in the association between AD biomarkers and cognitive decline.
    Koran MEI; Wagener M; Hohman TJ;
    Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline.
    Torosyan N; Mason K; Dahlbom M; Silverman DHS;
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1355-1363. PubMed ID: 28331953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Transition of Mild Cognitive Impairment Over Time: An AV45- and FDG-PET Study of Reversion and Conversion Phenomena.
    Ashraf-Ganjouei A; Moradi K; Faghani S; Abdolalizadeh A; Khomeijani-Farahani M; Fatehi F; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2021; 18(9):721-731. PubMed ID: 34819007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.